Li Wai Suen Christopher F D, Choy Matthew C, De Cruz Peter
Department of Gastroenterology, Austin Health, Melbourne, Australia.
Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, Australia.
Intest Res. 2024 Oct;22(4):397-413. doi: 10.5217/ir.2024.00003. Epub 2024 May 16.
Acute severe ulcerative colitis (ASUC) is a medical emergency that affects approximately 25% of patients with ulcerative colitis at some point in time in their lives. Outcomes of ASUC are highly variable. Approximately 30% of patients do not respond to corticosteroids and up to 50% of patients do not respond to rescue therapy (infliximab or cyclosporin) and require emergency colectomy. Data are emerging on infliximab dosing strategies, use of cyclosporin as a bridge to slower acting biologic agents and Janus kinase inhibition as primary and sequential therapy. In this review, we outline contemporary approaches to clinical management of ASUC in the setting of failure to respond to traditional rescue therapies.
急性重症溃疡性结肠炎(ASUC)是一种医疗急症,一生中约有25%的溃疡性结肠炎患者会在某个时间点受到影响。ASUC的预后差异很大。约30%的患者对皮质类固醇无反应,高达50%的患者对挽救治疗(英夫利昔单抗或环孢素)无反应,需要进行急诊结肠切除术。关于英夫利昔单抗给药策略、使用环孢素作为过渡到起效较慢的生物制剂的桥梁以及将 Janus 激酶抑制作为一线和序贯治疗的数据正在不断涌现。在本综述中,我们概述了在对传统挽救治疗无反应的情况下,ASUC临床管理的当代方法。